Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025

Sino Biological,Inc. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 511.45 million compared to CNY 464.95 million a year ago. Net income was CNY 110.18 million compared to CNY 99.32 million a year ago.Basic earnings per share from continuing operations was CNY 0.9058 compared to CNY 0.7787 a year ago.

Sino Biological released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, an increase of 10.94%

According to the Zhitong Finance APP, Sino Biological released its third-quarter report for 2025. The company's operating income for the first three quarters was 511 million yuan, a year-on-year increase of 10.00%. The net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 10.94%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 62.2531 million yuan, a year-on-year increase of 75.30%. The basic earnings per share were 0.9058 yuan

Sino Biological: The controlling shareholder Aileke pledged 3.70% of the company's shares

Sino Biological announced that the company's controlling shareholder, Lhasa Ailike Investment Consulting Co., Ltd., pledged 4.5 million shares of the company on September 4, 2025, accounting for 6.91% of its holdings and 3.70% of the company's total share capital. The pledge start date is September 4, 2025, and the purpose of the pledge is for financing. The pledged shares do not have significant asset restructuring or performance compensation obligations

Sino Biological released its performance for the first half of the year, with a net profit attributable to the parent company of 67.6863 million yuan, a decrease of 4.59%

According to the Zhitong Finance APP, Sino Biological released its semi-annual report for 2025, showing an operating income of 324 million yuan, a year-on-year increase of 6.15%. The net profit attributable to shareholders of the listed company was 67.6863 million yuan, a year-on-year decrease of 4.59%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 33.1225 million yuan, a year-on-year increase of 31.85%. The basic earnings per share were 0.5565 yuan

The CRO concept saw a short-term surge, with HC CHEMICAL hitting the limit up, and Kingchem, ChemPartner, R&G Pharma, Highfine, and Sino Biological all rising